BTG buys rival for $242M

The UK's BTG has announced plans to acquire Biocompatibles for £177 million, or about $242 million. With the acquisition, BTG gains access to Biocompatibles' oncology products, which include drug coated beads used to treat liver cancer, according to the Financial Times. BTG plans on investing heavily in Biocompatibles' products and development pipeline, the company said in a statement. Report

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.